Core Viewpoint - The company HaiXin Co., Ltd. has received approval from the National Medical Products Administration for its generic drug "Vitamin B6 Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Company Summary - HaiXin Co., Ltd. announced on December 26 that its subsidiary Jiangxi Gannan HaiXin Pharmaceutical Co., Ltd. has obtained the approval notice for the supplemental application of the chemical drug "Vitamin B6 Injection" [1] - The approval indicates that the drug meets the required standards for quality and efficacy, which is crucial for its market entry and competitiveness [1]

Core Viewpoint - The company announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the "Vitamin B6 Injection," which has passed the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval and Market Impact - The Vitamin B6 Injection is primarily used for the prevention and treatment of Vitamin B6 deficiency, as well as for conditions such as poisoning from isoniazid, pregnancy-related issues, radiation sickness, and vomiting caused by anticancer drugs [1] - The product is classified as a Category A drug under the national medical insurance and is included in the national essential drug list, with projected sales in public medical institutions in China expected to reach approximately RMB 304 million in 2024 [1] - Passing the consistency evaluation is expected to enhance the product's market competitiveness and provide valuable experience for future new drug development, although it will not have a significant impact on the company's current operating performance [1] Group 2: Market Considerations - The company highlighted that drug sales are influenced by national policies, bidding procurement, and market conditions, which introduces uncertainties [1]

Core Viewpoint - Ganhai Xin's vitamin B6 injection has passed the consistency evaluation of quality and efficacy for generic drugs, enhancing its market competitiveness, although it will not significantly impact the company's current operating performance [1] Company Summary - Ganhai Xin, a subsidiary of Haixin Co., has developed a vitamin B6 injection primarily used for preventing and treating vitamin B6 deficiency and as a nutritional supplement for specific populations [1] - The product adheres to the drug registration standards set by the National Medical Products Administration [1] Industry Summary - The estimated sales revenue for public medical institutions in China for vitamin B6 injections is approximately 304 million yuan in 2024 [1]

Core Viewpoint - The company announced that its subsidiary, Jiangxi Gannan Haixin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplement application of the chemical drug "Vitamin B6 Injection," which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] - The "Vitamin B6 Injection" is now positioned to enter the market, potentially increasing the company's revenue streams [1] - The successful completion of the consistency evaluation indicates the company's commitment to maintaining high-quality standards in its pharmaceutical offerings [1]

Group 1 - The company Shanghai Haixin Group Co., Ltd. has provided a guarantee for its wholly-owned subsidiary, Shanghai Haixin Logistics Co., Ltd., for a fixed asset loan of RMB 20 million from Shanghai Rural Commercial Bank, which will be used for the renovation of its factory [2][4] - The guarantee was approved by the company's board of directors during the eighth meeting of the eleventh session, with a maximum guarantee amount set at RMB 30 million [3][6] - The collateral for the loan is a property located at No. 121, Zhenye Road, Dongjing Town, Songjiang District, Shanghai [5][6] Group 2 - The loan is scheduled for a term from January 12, 2026, to January 11, 2031, and is aimed at meeting the financing needs for the factory renovation, aligning with national policies on urban renewal and industrial upgrading [4][6] - As of the announcement date, the total amount of guarantees provided by the company to its subsidiaries is RMB 143.75 million, which accounts for 3.32% of the company's audited net assets of RMB 4.334 billion for the year 2024, with no overdue guarantees or guarantees involved in litigation [6]

Core Viewpoint - HaiXin Co., Ltd. announced that as of the date of the announcement, the total amount of guarantees provided to its controlling subsidiary is 143.75 million yuan, which accounts for 3.32% of the company's audited net assets of 4.334 billion yuan [2] Summary by Categories - **Guarantee Amount**: The total guarantees provided by the company to its controlling subsidiary amount to 143.75 million yuan [2] - **Net Assets**: The guarantees represent 3.32% of the company's audited net assets, which are reported to be 4.334 billion yuan [2] - **Legal Status**: There are no overdue external guarantees, nor are there any external guarantees involved in litigation [2]

证券代码：600851 证券简称：海欣股份 公告编号：2025-034 900917 海欣 B 股 上海海欣集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次担保授权已经公司第十一届董事会第八次会议审议通过，具体授权额度如下： 担保对象及基本情况 | | 被担保人名称 | | 上海海欣物流有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | | 万元 2,000 | | | 担保对象 | 实际为其提供的担保余额 | | 2,000 万元 | | | | 是否在前期预计额度内 | √是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | √否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 24,000 | | 对外担保总额占上 ...

Market Overview - The participatory fund sector experienced a decline of 0.84% compared to the previous trading day, with Daheng Technology leading the drop [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Notable gainers included: - Zhongjia Group (Code: 000039) with a closing price of 9.35, up 10.00% and a trading volume of 1.9474 million shares, totaling 1.764 billion yuan [1] - Suzhou Gaoxin (Code: 600736) closed at 5.79, up 3.76% with a trading volume of 590,000 shares, totaling 345 million yuan [1] - Daheng Technology (Code: 600288) was the biggest loser, closing at 14.69, down 2.13% with a trading volume of 86,400 shares, totaling 129 million yuan [2] Capital Flow - The participatory fund sector saw a net outflow of 732 million yuan from institutional investors, while retail investors contributed a net inflow of 574 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their participation [2] Individual Stock Capital Flow - Zhongjia Group (Code: 000039) had a net inflow of 474 million yuan from institutional investors, representing 26.86% of its trading volume [3] - Fenghuo Communication (Code: 600498) experienced a net inflow of 76.36 million yuan from institutional investors, but a net outflow of 18.29 million yuan from speculative funds [3]

Group 1 - Company HaiXin Co., Ltd. responded to investor inquiries on November 24 regarding the number of shareholders, indicating that investors should refer to the company's periodic reports for this information [2]

Market Overview - The participation fund sector declined by 0.53% on November 14, with Changjiang Securities leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Individual Stock Performance - Notable gainers included: - Zhongshun Group (Code: 000039) with a closing price of 8.94, up 9.96% [1] - Guomai Technology (Code: 002093) with a closing price of 11.90, up 2.15% [1] - Major decliners included: - Changjiang Securities (Code: 000783) with a closing price of 8.80, down 2.98% [2] - Huatai Securities (Code: 601688) with a closing price of 22.17, down 2.93% [2] Capital Flow Analysis - The participation fund sector experienced a net outflow of 2.136 billion yuan from institutional investors, while retail investors saw a net inflow of 1.242 billion yuan [2] - The overall capital flow indicated that speculative funds had a net inflow of 894 million yuan [2] Detailed Capital Flow by Stock - Key stocks with significant capital flow: - Zhongshun Group had a net inflow of 597 million yuan from institutional investors, but a net outflow of 378 million yuan from speculative funds [3] - Industrial and Commercial Bank of China (Code: 601398) saw a net inflow of 145 million yuan from institutional investors [3] - Other stocks like Northeast Securities (Code: 000686) and Hanhua Technology (Code: 600226) showed mixed capital flows with both inflows and outflows from different investor types [3]